- Parent company: EMD Serono, Inc.
- Given via intravenous injection once every three months for a maximum of two-to-three years.
- The doses are limited to avoid the risk of cardiotoxicity (heart damage); risk of developing leukemia is also increased with long-term use, and women may have menstrual irregularities.
Novantrone is an immunosuppressant and destroys all rapidly dividing cells, including those in the immune system.
- Also used to treat cancer.
- Has been approved for individuals with secondary-progressive MS (SPMS), progressive-relapsing MS (PRMS), and worsening RRMS; not indicated for PPMS.
- Used by some physicians to treat patients whose disease is rapidly worsening, or who are not responding favorably to the first line of treatment (Avonex, Betaseron, Copaxone, or Rebif).
- Previous studies have shown a significant reduction in active lesions and a reduction in disease progression.